Cargando…

Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial

BACKGROUND: High-permeability pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS) and is frequently accompanied by impaired alveolar fluid clearance (AFC). AP301 enhances AFC by activating epithelial sodium channels (ENaCs) on alveolar epithelial cells, and we investigated it...

Descripción completa

Detalles Bibliográficos
Autores principales: Krenn, Katharina, Lucas, Rudolf, Croizé, Adrien, Boehme, Stefan, Klein, Klaus Ulrich, Hermann, Robert, Markstaller, Klaus, Ullrich, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531100/
https://www.ncbi.nlm.nih.gov/pubmed/28750677
http://dx.doi.org/10.1186/s13054-017-1795-x
_version_ 1783253343290785792
author Krenn, Katharina
Lucas, Rudolf
Croizé, Adrien
Boehme, Stefan
Klein, Klaus Ulrich
Hermann, Robert
Markstaller, Klaus
Ullrich, Roman
author_facet Krenn, Katharina
Lucas, Rudolf
Croizé, Adrien
Boehme, Stefan
Klein, Klaus Ulrich
Hermann, Robert
Markstaller, Klaus
Ullrich, Roman
author_sort Krenn, Katharina
collection PubMed
description BACKGROUND: High-permeability pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS) and is frequently accompanied by impaired alveolar fluid clearance (AFC). AP301 enhances AFC by activating epithelial sodium channels (ENaCs) on alveolar epithelial cells, and we investigated its effect on extravascular lung water index (EVLWI) in mechanically ventilated patients with ARDS. METHODS: Forty adult mechanically ventilated patients with ARDS were included in a randomized, double-blind, placebo-controlled trial for proof of concept. Patients were treated with inhaled AP301 (n = 20) or placebo (0.9% NaCl; n = 20) twice daily for 7 days. EVLWI was measured by thermodilution (PiCCO®), and treatment groups were compared using the nonparametric Mann–Whitney U test. RESULTS: AP301 inhalation was well tolerated. No differences in mean baseline-adjusted change in EVLWI from screening to day 7 were found between the AP301 and placebo group (p = 0.196). There was no difference in the PaO(2)/FiO(2) ratio, ventilation pressures, Murray lung injury score, or 28-day mortality between the treatment groups. An exploratory subgroup analysis according to severity of illness showed reductions in EVLWI (p = 0.04) and ventilation pressures (p < 0.05) over 7 days in patients with initial sequential organ failure assessment (SOFA) scores ≥11 inhaling AP301 versus placebo, but not in patients with SOFA scores ≤10. CONCLUSIONS: There was no difference in mean baseline-adjusted EVLWI between the AP301 and placebo group. An exploratory post-hoc subgroup analysis indicated reduced EVLWI in patients with SOFA scores ≥11 receiving AP301. These results suggest further confirmation in future clinical trials of inhaled AP301 for treatment of pulmonary edema in patients with ARDS. TRIAL REGISTRATION: The study was prospectively registered at clinicaltrials.gov, NCT01627613. Registered 20 June 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1795-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5531100
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55311002017-08-02 Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial Krenn, Katharina Lucas, Rudolf Croizé, Adrien Boehme, Stefan Klein, Klaus Ulrich Hermann, Robert Markstaller, Klaus Ullrich, Roman Crit Care Research BACKGROUND: High-permeability pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS) and is frequently accompanied by impaired alveolar fluid clearance (AFC). AP301 enhances AFC by activating epithelial sodium channels (ENaCs) on alveolar epithelial cells, and we investigated its effect on extravascular lung water index (EVLWI) in mechanically ventilated patients with ARDS. METHODS: Forty adult mechanically ventilated patients with ARDS were included in a randomized, double-blind, placebo-controlled trial for proof of concept. Patients were treated with inhaled AP301 (n = 20) or placebo (0.9% NaCl; n = 20) twice daily for 7 days. EVLWI was measured by thermodilution (PiCCO®), and treatment groups were compared using the nonparametric Mann–Whitney U test. RESULTS: AP301 inhalation was well tolerated. No differences in mean baseline-adjusted change in EVLWI from screening to day 7 were found between the AP301 and placebo group (p = 0.196). There was no difference in the PaO(2)/FiO(2) ratio, ventilation pressures, Murray lung injury score, or 28-day mortality between the treatment groups. An exploratory subgroup analysis according to severity of illness showed reductions in EVLWI (p = 0.04) and ventilation pressures (p < 0.05) over 7 days in patients with initial sequential organ failure assessment (SOFA) scores ≥11 inhaling AP301 versus placebo, but not in patients with SOFA scores ≤10. CONCLUSIONS: There was no difference in mean baseline-adjusted EVLWI between the AP301 and placebo group. An exploratory post-hoc subgroup analysis indicated reduced EVLWI in patients with SOFA scores ≥11 receiving AP301. These results suggest further confirmation in future clinical trials of inhaled AP301 for treatment of pulmonary edema in patients with ARDS. TRIAL REGISTRATION: The study was prospectively registered at clinicaltrials.gov, NCT01627613. Registered 20 June 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1795-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-27 /pmc/articles/PMC5531100/ /pubmed/28750677 http://dx.doi.org/10.1186/s13054-017-1795-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Krenn, Katharina
Lucas, Rudolf
Croizé, Adrien
Boehme, Stefan
Klein, Klaus Ulrich
Hermann, Robert
Markstaller, Klaus
Ullrich, Roman
Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial
title Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial
title_full Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial
title_fullStr Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial
title_full_unstemmed Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial
title_short Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial
title_sort inhaled ap301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase iia randomized placebo-controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531100/
https://www.ncbi.nlm.nih.gov/pubmed/28750677
http://dx.doi.org/10.1186/s13054-017-1795-x
work_keys_str_mv AT krennkatharina inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial
AT lucasrudolf inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial
AT croizeadrien inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial
AT boehmestefan inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial
AT kleinklausulrich inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial
AT hermannrobert inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial
AT markstallerklaus inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial
AT ullrichroman inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial